OBJECT: Choroid plexus tumors (CPTs) are rare intracranial neoplasms that constitute approximately 2%-5% of all pediatric brain tumors. Most of these tumors present with severe hydrocephalus. The optimal perioperative management and oncological care remain a matter of debate. The authors present the epidemiological and clinical features of CPTs from a 20-year single-institutional experience. METHODS: A total of 39 consecutive patients with pathologically proven CPTs (31 choroid plexus papillomas [CPPs] and 8 choroid plexus carcinomas [CPCs]) were included in this series. Patient demographics, clinical presentation, comorbidities, indications for surgery, radiological studies, tumor location, and all operative variables were reviewed for each case. Multivariate regression analysis was performed to identify independent predictors of tumor recurrence and survival. RESULTS: The overall mean age (± SD) was 13.13 ± 19.59 years (15.27 ± 21.10 years in the CPP group and 3.66 ± 3.59 years in the CPC group). Hydrocephalus was noted at presentation in 34% of patients. The most common presenting symptoms were headache (32%) and nausea/vomiting (26%). Gross-total resection (GTR) was achieved in 86% of CPPs and in 71% of CPCs (p = 0.57). There was 100% survival in patients with CPPs observed at the 5- and 10-year follow-up and 71% survival in patients with CPCs at the 5-year follow-up. In a multivariate regression analysis, a diagnosis of papilloma, preoperative vision changes, or hydrocephalus; right ventricle tumor location; and GTR were all independently associated with a decreased likelihood of tumor recurrence at last follow-up. CONCLUSIONS: The authors' study suggests that patients with CPCs are more likely to experience local recurrence and metastasis; hence, GTR with chemotherapy and radiotherapy, particularly for CPCs, is pivotal in preventing recurrence and prolonging survival. While GTR was important for local control following resection of CPPs, it had a minimal effect on prolonging survival in this patient cohort.
OBJECT: Choroid plexus tumors (CPTs) are rare intracranial neoplasms that constitute approximately 2%-5% of all pediatric brain tumors. Most of these tumors present with severe hydrocephalus. The optimal perioperative management and oncological care remain a matter of debate. The authors present the epidemiological and clinical features of CPTs from a 20-year single-institutional experience. METHODS: A total of 39 consecutive patients with pathologically proven CPTs (31 choroid plexus papillomas [CPPs] and 8 choroid plexus carcinomas [CPCs]) were included in this series. Patient demographics, clinical presentation, comorbidities, indications for surgery, radiological studies, tumor location, and all operative variables were reviewed for each case. Multivariate regression analysis was performed to identify independent predictors of tumor recurrence and survival. RESULTS: The overall mean age (± SD) was 13.13 ± 19.59 years (15.27 ± 21.10 years in the CPP group and 3.66 ± 3.59 years in the CPC group). Hydrocephalus was noted at presentation in 34% of patients. The most common presenting symptoms were headache (32%) and nausea/vomiting (26%). Gross-total resection (GTR) was achieved in 86% of CPPs and in 71% of CPCs (p = 0.57). There was 100% survival in patients with CPPs observed at the 5- and 10-year follow-up and 71% survival in patients with CPCs at the 5-year follow-up. In a multivariate regression analysis, a diagnosis of papilloma, preoperative vision changes, or hydrocephalus; right ventricle tumor location; and GTR were all independently associated with a decreased likelihood of tumor recurrence at last follow-up. CONCLUSIONS: The authors' study suggests that patients with CPCs are more likely to experience local recurrence and metastasis; hence, GTR with chemotherapy and radiotherapy, particularly for CPCs, is pivotal in preventing recurrence and prolonging survival. While GTR was important for local control following resection of CPPs, it had a minimal effect on prolonging survival in this patient cohort.
Authors: R J Packer; G Perilongo; D Johnson; L N Sutton; G Vezina; R A Zimmerman; J Ryan; G Reaman; L Schut Journal: Cancer Date: 1992-01-15 Impact factor: 6.860
Authors: E Chow; D A Reardon; A B Shah; J J Jenkins; J Langston; R L Heideman; R A Sanford; L E Kun; T E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 1999-05-01 Impact factor: 7.038
Authors: Michal Bahar; Hasan Hashem; Tanya Tekautz; Sarah Worley; Anne Tang; Peter de Blank; Johannes Wolff Journal: J Neurooncol Date: 2017-03-13 Impact factor: 4.130
Authors: Annalisa Passariello; Maria Tufano; Pietro Spennato; Lucia Quaglietta; Antonio Verrico; Roberta Migliorati; Giuseppe Cinalli Journal: Childs Nerv Syst Date: 2015-04-12 Impact factor: 1.475
Authors: Matthew Z Sun; Michael E Ivan; Aaron J Clark; Michael C Oh; Arthur R Delance; Taemin Oh; Michael Safaee; Gurvinder Kaur; Orin Bloch; Annette Molinaro; Nalin Gupta; Andrew T Parsa Journal: J Neurooncol Date: 2013-10-29 Impact factor: 4.130
Authors: A Siegfried; S Morin; C Munzer; M B Delisle; M Gambart; S Puget; C A Maurage; C Miquel; C Dufour; P Leblond; N André; D Figarella Branger; J Kanold; J-L Kemeny; C Icher; A Vital; E Uro Coste; A I Bertozzi Journal: J Neurooncol Date: 2017-07-04 Impact factor: 4.130